Matinas BioPharma (MTNB) shelved development of a prescription formulation of fish oil three years ago. The tiny company, with a stock that trades for pennies, decided investors would be more interested in its drug delivery technology and a small pipeline of anti-infectives.

But then Amarin (AMRN) happened. Amarin’s stock price soared to all-time highs — adding nearly $5 billion in market cap — on the readout of a large clinical trial showing its proprietary fish oil drug, called Vascepa, cut the risk of bad cardiovascular events like heart attacks and stroke in patients by an astounding 25 percent.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I am sure that there is nothing to prove. Fish oil is useless against heart diseases. It’s a myth that fish oil is so universal. I don’t believe Amarin. They gain money only.

  • I follow the news after Amarin. It’s all very interesting about Vascepa. Fish oil they are positioned as purified. Clinical trials are highly questionable. Amarin employees participated Vascepa’s clinical trials. In general, the company has raised the hype in the press, the stock cost has rised.

    • I am sure that there is nothing to prove. Fish oil is useless against heart diseases. It’s a myth that fish oil is so universal. I don’t believe Amarin. They gain money only .

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy